The global pharmaceutical industry experienced a 113% rise in company filings mentions of cybersecurity in Q1 2023 compared with the previous quarter, with the highest share accounted for by Alnylam Pharmaceuticals with 114% year-on-year increase, according to GlobalData’s analysis of over 667 pharmaceutical company filings. GlobalData’s cybersecurity in Healthcare – Thematic Research market report helps get a detailed understanding on how cybersecurity impacts the value chain in the pharmaceutical sector, and the leading cybersecurity adopters and vendors in the market. Buy the report here.
Notably, cybersecurity was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of environment and robotics, according to GlobalData.
Of the 50 leading companies in the pharmaceutical industry, Alnylam Pharmaceuticals had the greatest increase in references for cybersecurity in Q1 2023, compared with the previous quarter. GlobalData identified 21 cybersecurity-related sentences in the company's filings, an increase of 100% in Q1 2023 compared with Q4 2022. Sarepta Therapeutics’s mentions of cybersecurity rose by 100% to 19 and Regeneron Pharmaceuticals’s by 100% to 15 and Horizon Therapeutics’s by 100% to 10 and Incyte’s by 100% to 9.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for cybersecurity in Q1 2023 was 100.
To further understand GlobalData's analysis on Cybersecurity in Healthcare - Thematic Research market, buy the report here.